Kodiak Sciences Inc. (KOD)Healthcare | Biotechnology | Palo Alto, United States | NasdaqGM
88.12 USD
+7.03
(8.669%)
⇧
(Oct. 15, 2026, 4 p.m.
EDT)
|
Hot Take ↕ | Oct. 10, 2026, 5:15 a.m. EDT
The stock has rallied sharply following positive clinical data, trading well above its 50-day moving average and creating a crowded short-term trade. While the multi-year trajectory shows a net gain and the latest annual performance is strongly positive, the underlying fundamentals remain unprofitable with negative earnings and cash flow. The options market reflects this tension with elevated implied volatility and heavy put buying at deep strikes, suggesting investors are hedging against a potential correction. This is a high-conviction momentum play on a turnaround story rather than a stable income investment, with significant valuation risk given the 100x price-to-book multiple. |
| Model | MAE |
|---|---|
| AutoARIMA ✓ | 0.215482 |
| MSTL | 0.216008 |
| AutoETS | 0.216353 |
| AutoTheta | 0.249871 |
Forecast horizon: 45 days | Selected: AutoARIMA
| Forecast Reliability | |
|---|---|
| Score | 13% |
| H-stat | 121.36 |
| Ljung-Box p | 0.000 |
| Jarque-Bera p | 0.000 |
| Excess Kurtosis | 1.76 |
| Attribute | Value |
|---|---|
| Sector | Healthcare |
| Debt to Equity Ratio | 86.349 |
| Market Cap | 5,538,294,272 |
| Forward P/E | -25.65 |
| Beta | 2.04 |
| Website | https://kodiak.com |
As of Oct. 10, 2026, 5:15 a.m. EDT: Implied volatility is elevated across all expirations (75-80%), signaling high uncertainty. Call volume is notably concentrated at the $110 strike, suggesting speculative upside bets, while put volume remains heavy at the $90 strike and deep ITM levels ($15), indicating hedging or downside protection. The ATM call volume spike aligns with the recent price surge.
| Attribute | Value |
|---|---|
| 52 Week Change | 4.751064 |
| Address1 | 1,250 Page Mill Road |
| All Time High | 171.21 |
| All Time Low | 1.37 |
| Ask | 55.16 |
| Ask Size | 2 |
| Audit Risk | 7 |
| Average Analyst Rating | 1.4 - Strong Buy |
| Average Daily Volume10 Day | 2,101,210 |
| Average Daily Volume3 Month | 1,652,734 |
| Average Volume | 1,652,734 |
| Average Volume10Days | 2,101,210 |
| Beta | 2.035 |
| Bid | 30.95 |
| Bid Size | 2 |
| Board Risk | 9 |
| Book Value | 0.974 |
| City | Palo Alto |
| Compensation As Of Epoch Date | 1,767,139,200 |
| Compensation Risk | 9 |
| Country | United States |
| Crypto Tradeable | 0 |
| Currency | USD |
| Current Price | 88.12 |
| Current Ratio | 2.489 |
| Custom Price Alert Confidence | HIGH |
| Date Short Interest | 1,790,726,400 |
| Day High | 88.5 |
| Day Low | 79.06 |
| Debt To Equity | 86.349 |
| Display Name | Kodiak Sciences |
| Dividend Yield | 0.0 |
| Earnings Call Timestamp End | 1,711,657,800 |
| Earnings Call Timestamp Start | 1,711,657,800 |
| Earnings Timestamp End | 1,794,513,600 |
| Earnings Timestamp Start | 1,794,513,600 |
| Ebitda | -230,978,000 |
| Ebitda Margins | 0.0 |
| Enterprise To Ebitda | -23.613 |
| Enterprise Value | 5,453,977,600 |
| Eps Current Year | -3.98086 |
| Eps Forward | -3.43556 |
| Eps Trailing Twelve Months | -4.19 |
| Esg Populated | 0 |
| Exchange | NGM |
| Exchange Data Delayed By | 15 |
| Exchange Timezone Name | America/New_York |
| Exchange Timezone Short Name | EDT |
| Fifty Day Average | 51.909 |
| Fifty Day Average Change | 36.211002 |
| Fifty Day Average Change Percent | 0.6975862 |
| Fifty Two Week Change Percent | 475.10638 |
| Fifty Two Week High | 104.0 |
| Fifty Two Week High Change | -15.879997 |
| Fifty Two Week High Change Percent | -0.15269229 |
| Fifty Two Week Low | 13.95 |
| Fifty Two Week Low Change | 74.170006 |
| Fifty Two Week Low Change Percent | 5.3168464 |
| Fifty Two Week Range | 13.95 - 104.0 |
| Financial Currency | USD |
| First Trade Date Milliseconds | 1,538,659,800,000 |
| Float Shares | 36,864,016 |
| Forward Eps | -3.43556 |
| Forward P E | -25.649385 |
| Free Cashflow | -58,392,248 |
| Full Exchange Name | NasdaqGM |
| Full Time Employees | 141 |
| Fullday Change | 7.3600006 |
| Fullday Change Percent | 9.076336 |
| Fullday Price | 88.12 |
| Gmt Off Set Milliseconds | -14,400,000 |
| Governance Epoch Date | 1,790,812,800 |
| Gross Margins | 0.0 |
| Has Pre Post Market Data | 1 |
| Held Percent Insiders | 0.051609997 |
| Held Percent Institutions | 1.05539 |
| Implied Shares Outstanding | 62,849,457 |
| Industry | Biotechnology |
| Industry Disp | Biotechnology |
| Industry Key | biotechnology |
| Is Earnings Date Estimate | 1 |
| Language | en-US |
| Last Fiscal Year End | 1,767,139,200 |
| Long Business Summary | Kodiak Sciences Inc., a clinical stage biopharmaceutical company, engages in the research, development, and commercialization of therapeutics to treat retinal diseases. Its lead product candidate is tarcocimab tedromer (KSI-301), an anti-vascular endothelial growth factor (VEGF) antibody biopolymer that has complete Phase 3 clinical study to treat high prevalence retinal vascular diseases; and in Phase 3 clinical study for the treatment of diabetic retinopathy, wet age-related macular degeneration (AMD), retinal vein occlusion, and diabetic macular edema, as well as in Phase 2/3 clinical study to treat wet AMD. The company's preclinical stage product candidate includes KSI-501, an anti- interleukin-6 (IL-6) and VEGF-trap bispecific antibody biopolymer conjugate for high prevalence retinal vascular diseases; and KSI-101 (KSI-501P), a bispecific protein targeting IL-6 and VEGF developed for patients who have retinal fluid and inflammation. The company was formerly known as Oligasis, LLC and changed its name to Kodiak Sciences Inc. in September 2015. Kodiak Sciences Inc. was incorporated in 2009 and is based in Palo Alto, California. |
| Long Name | Kodiak Sciences Inc. |
| Market | us_market |
| Market Cap | 5,538,294,272 |
| Market State | PRE |
| Max Age | 86,400 |
| Message Board Id | finmb_321992085 |
| Most Recent Quarter | 1,782,777,600 |
| Net Income To Common | -241,994,000 |
| Next Fiscal Year End | 1,798,675,200 |
| Non Diluted Market Cap | 2,124,311,646 |
| Number Of Analyst Opinions | 6 |
| Open | 81.3 |
| Operating Cashflow | -158,504,992 |
| Operating Margins | 0.0 |
| Overall Risk | 9 |
| Phone | 650 281 0850 |
| Previous Close | 81.09 |
| Price Eps Current Year | -22.135921 |
| Price Hint | 2 |
| Price To Book | 90.47228 |
| Profit Margins | 0.0 |
| Quick Ratio | 2.386 |
| Quote Source Name | Nasdaq Real Time Price |
| Quote Type | EQUITY |
| Recommendation Key | strong_buy |
| Recommendation Mean | 1.42857 |
| Region | US |
| Regular Market Change | 7.03001 |
| Regular Market Change Percent | 8.66939 |
| Regular Market Day High | 88.5 |
| Regular Market Day Low | 79.06 |
| Regular Market Day Range | 79.06 - 88.5 |
| Regular Market Open | 81.3 |
| Regular Market Previous Close | 81.09 |
| Regular Market Price | 88.12 |
| Regular Market Time | 1,792,094,401 |
| Regular Market Volume | 1,394,517 |
| Return On Assets | -0.60446 |
| Return On Equity | -3.68371 |
| Sand P52 Week Change | 0.16207206 |
| Sector | Healthcare |
| Sector Disp | Healthcare |
| Sector Key | healthcare |
| Share Holder Rights Risk | 8 |
| Shares Outstanding | 62,849,457 |
| Shares Percent Shares Out | 0.1492 |
| Shares Short | 9,376,012 |
| Shares Short Previous Month Date | 1,788,134,400 |
| Shares Short Prior Month | 10,780,926 |
| Short Name | Kodiak Sciences Inc |
| Short Percent Of Float | 0.2361 |
| Short Ratio | 3.12 |
| Source Interval | 15 |
| State | CA |
| Symbol | KOD |
| Target High Price | 145.0 |
| Target Low Price | 103.0 |
| Target Mean Price | 121.66667 |
| Target Median Price | 122.0 |
| Total Cash | 125,903,000 |
| Total Cash Per Share | 2.007 |
| Total Debt | 52,756,000 |
| Tradeable | 0 |
| Trailing Annual Dividend Rate | 0.0 |
| Trailing Annual Dividend Yield | 0.0 |
| Trailing Eps | -4.19 |
| Trailing Peg Ratio | None |
| Triggerable | 1 |
| Two Hundred Day Average | 38.2446 |
| Two Hundred Day Average Change | 49.875404 |
| Two Hundred Day Average Change Percent | 1.3041162 |
| Type Disp | Equity |
| Volume | 1,394,517 |
| Website | https://kodiak.com |
| Zip | 94,304 |